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Abstract 
Zahilis Mazzochette 
A STUDY OF ALBENDAZOLE AND ARTEMISININ DRUGS UNDER 
ELECTROCHEMICAL OXIDATION 
2017-2018 
Amos Mugweru, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
This work is aimed to investigate the metabolic behavior of albendazole and 
artemisinin. The electrochemical oxidation and reduction of these drugs were performed 
on electrode materials to mimic their metabolism in vivo using cyclic voltammetry and 
bulk electrolysis analysis. The oxidation of albendazole on gold electrode surface yielded 
albendazole sulfoxide and albendazole sulfone which are the main metabolites of this 
drug in vivo. Reduction of artemisinin on glassy carbon (GC) electrode surface yielded 
dihydroartemisinin and deoxy artemisinin. The formation of these products was 
monitored using liquid chromatography and mass spectrometry techniques. The redox 
processes for both drugs were shown to be irreversible and diffusion controlled. 
Bioactivation of artemisinin by hemoglobin was detected using a GC/carbon nanofibers 
(CNFs)/Hb biosensor. The catalytic effect of hemoglobin lowered the reduction potential 
of artemisinin by 475 mV. The apparent Michaelis-Menten constant (Km) was 0.093 mM 
which shows excellent biological activity of the CNFs bound hemoglobin. Additionally, 
the biosensor showed a linear relationship with increasing artemisinin concentration. 
Therefore, it can be useful to determine concentration of this drug in solution and 
matrices such as biological fluids.   
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Chapter 1 
An Introduction to Electrochemical Analysis of Pharmaceuticals 
Electroanalysis of Pharmaceuticals 
Application of electrochemical techniques to solve chemical problems started 
with the invention of polarography in 1922 by Jaroslav Heyrovsky, and the polarograph, 
one of the first automated analytical devices, by Heyrovsky and Shikata 1. Heyrovsky’s 
invention had a significant impact on the advancement of electroanalysis. He was 
awarded the Nobel Prize for chemistry in 1959 for this contribution 2. Electroanalysis 
experienced its greatest advancement between the 1950s and 1970s with the development 
of new methods and instrumentation as well as interest in improving the electrode 
surfaces, which lead to the development of electrochemical sensors 1-2. Electrochemical 
analysis has found applications in a wide variety of industries such as metal and 
pharmaceutical industries, as well as in research, environmental, and occupational health 
fields 3-4. 
Electrochemical techniques have been utilized for the analysis of pharmaceuticals 
since the 1960s 5. The interest in these techniques for drug analysis has increased 
remarkably since then. The increase in popularity can be attributed to the development of 
more sophisticated instrumentation and a better understanding of the techniques 
themselves 6. Electrochemical techniques offer many advantages for the analysis of 
pharmaceuticals including excellent sensitivity at very low concentration, rapid analysis, 
small sample volumes, and easy sample preparation 5. They offer excellent methods for 
concentration determination of drugs in pure solutions, dosage forms, and biological 
fluids. Additionally, electrochemical methods are very useful to obtain information about 
drugs’ pharmacokinetics, mechanism of drug action, and electron transfer parameters 7. 
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Electrochemical Techniques Often used for Drug Analysis 
Potentiometry, coulometry, and voltammetry are popular electrochemical 
techniques used for analysis of pharmaceuticals. Potentiometry methods measure the 
potential of a solution, between the working and reference electrodes, due to an applied 
controlled current. The difference in potential between the electrodes is used to determine 
the concentration of the analyte or analytes in solution. Coulometric titrations involve the 
generation of a chemical reactant at the electrode surface. Then, the generated reactant 
undergoes a chemical reaction with the analyte. Control potential coulometry is often 
referred to as bulk electrolysis. This technique will be described in more details later in 
this chapter as it was used in drug oxidation. Voltammetric methods are based on the 
application of a constant or varying potential at the surface of a working electrode and 
measuring the resulting current. The potential or voltage applied at the working 
electrode’s surface serves as the driving force to carry out reduction or oxidation 
reactions 8. In voltammetry, the applied potential is the controlled parameter, and it can 
be adjusted according to the reductive or oxidative properties of the drug species being 
analyzed. Two different waveforms can be obtained using voltammetry a time-voltage, 
and a current-voltage plot. A potential versus time waveform is obtained when a varying 
voltage is applied over a period of time. The second plot is obtained by applying a 
potential and measuring the current produced. The resulting curve is called a 
voltammogram from which information about the electrochemical properties of the 
species being analyzed can be obtained 8. Voltammetry is very popular for the analysis of 
drugs and pharmaceuticals 4. The choice of voltammetric method depends on the type of 
analyte and parameters to be determined. Table 1 shows different types of voltammetric 
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methods that have been used for the analysis of pharmaceuticals. In this work, cyclic 
voltammetry, amperometry, and bulk electrolysis are the electroanalytical methods used 
to study the redox behavior of albendazole and artemisinin. Therefore, a detailed 
discussion of these methods is offered. 
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Table 1  
Voltammetric methods used for quantification, mode of action, and kinetic studies of 
pharmaceuticals. 
 
       
 Method                             Drug                                   Type of Study               References 
 
 
Cyclic Voltammetry 
(CV) 
 
Cephalexin, 
Daunomycin, Dopamine 
Acetaminophen 
Chloroquine 
 
Quantification, 
Mechanism of action, 
Electrochemical 
behavior, Kinetics 
 
 
 
9-13 
Square wave 
Voltammetry (SWV) 
Nitrofurantoin, 
Riboflavin, Doxazosin 
Nandrolone 
Ceftazidime 
 
Quantification, 
Electrochemical 
behavior 
 
14-19 
 
 
Anodic Stripping 
Voltammetry (ASV) 
 
Dopamine, Doxazosin 
 
Quantification 
 
 
14, 16 
Cathodic Striping 
Voltammetry (CSV) 
Chlordiazepoxide 
Norﬂoxacine, Enoxacine 
Quantification, 
Electrochemical 
behavior 
 
20-21 
Adsorptive Stripping 
Square Wave 
Voltammetry 
(AdSSWV) 
 
Carvedilol, Levoﬂoxacin 
Metoclopramide 
Electrochemical 
behavior, 
quantification 
 
22-24 
 
 
Differential Pulse 
Voltammetry (DPV) 
 
Nandrolone, Bergenin, 
Trimebutine, Ceftazidime  
 
Electrochemical 
behavior, 
quantification 
15, 17 
25-26 
Differential Pulse 
Polarography (DPP) 
Artemether, Ciclopirox 
olamine 
Quantification 27-28 
 
 
Amperometry 
 
Isoniazid, Ascorbic acid 
Sodium metabisulfite 
Electrochemical 
behavior, 
quantification 
 
29-31 
Adsorptive Striping 
Voltammetry (ASV) 
Ofloxacin, 
Fluoroquinolones 
 
Quantification 32 
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Cyclic voltammetry. Cyclic voltammetry (CV) is a versatile analytical technique 
widely used in many areas of electroanalytical chemistry 4. CV is especially popular for 
the analysis of drugs and pharmaceutical. In fact, it is among the first experiments carried 
out on drugs that are electro-active 33. Cyclic voltammetry can be used to determine 
concentration of analytes, and it is especially useful for the study of redox reactions and 
homogeneous chemical reactions coupled to electron transfer processes 34. During a CV 
experiment, the potential of the working electrode is ramped linearly versus time. The 
voltage applied to the working electrode is increased from an initial value Einitial to a 
predetermined limit, Elimit (the switching potential).  At this point, the direction of the 
scan is reversed completing one full cycle. The scanning can be stopped at this point, or a 
series of cycles between Einitial and Elimit can be performed. Repeated scanning is very 
useful to probe the stability of modified working electrodes 35. Furthermore, changes that 
appear on repetitive scans can reveal information about reaction mechanisms 8. 
Amperometry. Amperometry is classified as a voltammetric method. In 
amperometry, a constant reducing, or oxidizing potential is applied, and the resulting 
steady-state current is usually measured as a function of time 36. The magnitude of the 
resulting current correlates with the concentration of the oxidized or reduced analyte. 
Therefore, this technique is reliable and efficient to determine the concentration of one or 
numerous electroactive substances in solution by selectively choosing the magnitude of 
the applied potential and electrode material 36. Amperometry is also widely used for the 
analysis of electrochemical sensors and biosensors 36.  
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Bulk electrolysis. Control potential coulometry is referred to as bulk electrolysis. 
With this technique, a constant potential is applied to oxidize or reduce the substance of 
interest completely. A large working electrode with a surface area about one hundred 
times larger than a standard electrode is used to speed up the electrochemical conversion. 
The experiments are carried out under stirring conditions to aid transport of electroactive 
material to the electrode surface. “In controlled potential coulometry, the potential of the 
working electrode is maintained at a constant level such that the analyte conducts charge 
across the electrode-solution interface. The charge required to convert the analyte to its 
reaction products is then determined by integrating the current-versus-time curve during 
the electrolysis” 37. The amount of charge measured during the experiment is used to 
determine the concentration of analyte in solution. Therefore, controlled potential 
coulometry is a very valuable technique for quantitative analysis 38. This technique can be 
used for synthetic purposes as long as the product is neutral and can be isolated from the 
electrolyte solution. If the products cannot be isolated, then analytical techniques such as 
UV-Vis, NMR, HPLC, and mass spectrometry (MS) can be utilized to analyze them in 
solution 38. In this work, bulk electrolysis was used to completely electrolyzed samples of 
albendazole and artemisinin. The electrolysis products were analyzed using HPLC-MS. 
The Electrochemical Cell 
 Most electrochemical analysis of pharmaceuticals takes place in a three-electrode 
electrochemical cell which consists of a working electrode, an auxiliary or counter 
electrode, a reference electrode, and a supporting electrolyte. Redox reactions take place 
on the surface of the working electrode. The choice of working electrode depends on the 
nature of the analyte and the type of analysis to be performed. For example, cyclic 
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voltammetry is performed using working electrodes with a small surface area such as a 
standard gold, glassy carbon or platinum electrode (Figure 1a) while bulk electrolysis can 
be performed efficiently and rapidly by using a working electrode with a large surface 
area (Figure 1b). Standard working electrodes are mostly covered with insulating material 
just leaving a carefully controlled circular area exposed (about 1mm wide) where 
the reaction takes place. The auxiliary electrode is usually a platinum electrode, and it is 
needed to complete the circuit along with the working electrode. The reference electrode 
is used to measure the applied potential and does not pass any current. A supportive 
electrolyte is used to avoid migration of the species of interest through the solution. In 
some experiments, the supportive electrolyte can be used as a solvent.  
 
 
 
 
 
 
 
8 
 
 
 
 
 
Figure 1. Electrochemical cells: a) a typical voltammetry cell. b) Bulk electrolysis cell, 
featuring a large carbon working electrode.  
 
 
       
a) 
       
b) 
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Research Objective 
Understanding the electrochemical behavior of pharmacologically active 
molecules is of high importance since metabolic pathways of these molecules undergo 
redox transformations 39. Due to the similarities between biological and electrochemical 
reactions, it can be assumed that redox mechanisms taking place at the electrode surface 
and inside the body happen through similar processes. Therefore, the redox properties of 
drug molecules can give us insight into their metabolic fate and pharmacological activity 
in vivo 33. This study is aimed to use chromatographic and electroanalytical techniques to 
elucidate mechanistic parameters from the redox reactions of albendazole and 
artemisinin. Both albendazole and artemisinin have been reported as potential anticancer 
agents 40-41. A clear understanding of the electron transfer processes of these drugs is 
fundamental to better understand their anticancer properties and for the development of 
more potent analogs. 
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Chapter 2 
Electrochemical Oxidation of Albendazole 
Introduction 
Albendazole (ABZ) is a broad spectrum benzimidazole carbamate used for the treatment 
of helminths and diseases such as neurocysticercosis, strongyloidiasis, and 
microsporidiosis caused by such parasites 42-43. Albendazole has been in use for about 40 
years in humans and animals with few side effects among them mild gastrointestinal 
discomfort, dizziness, and rash 44. ABZ is a prodrug which is oxidized by liver enzymes 
and transformed into albendazole sulphoxide (ASOX) its pharmacologically active 
metabolite. Albendazole sulphoxide is further oxidized into albendazole sulphone 
(ASON) an inactive metabolite 44-45 (Figure 2). Albendazole works by selectively binding 
to parasites’ ß-tubulin preventing the formation of microtubules and stopping cell 
division. It also impairs glucose uptake leading to energy depletion and parasite death 46-
47. Albendazole’s solubility in aqueous solution is very poor due to the nature of its 
molecular structure hence high concentration of this drug is administered to improve 
absorption and achieve therapeutic levels 48-49. Pharmacokinetics of albendazole have 
been studied in both human and animals. The rate of absorption of albendazole was found 
to be erratic and varies greatly between individuals and animal species 49-50. There is 
continued interest in the study of albendazole’s properties and metabolism. In fact, there 
has been extensive research in developing attractive and fast methods for studying ABZ 
and its metabolites. Several reported analytical techniques for the analysis of albendazole 
include ultrahigh performance LC coupled with a mass spectroscopy detector, high-
performance liquid chromatographic (HPLC) 51-53, solid phase extraction coupled with 
11 
 
HPLC, and electrochemical studies 54-55. In this chapter, the electrochemical oxidation of 
albendazole is carried out to elucidate significant kinetic parameters helpful for further 
understanding of its metabolic fate. 
 
 
 
 
Figure 2. Albendazole and its metabolites: Albendazole sulphoxide and albendazole 
sulphone 39. 
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Experimental Methods 
Chemicals. Albendazole was purchased from Sigma Aldrich. Tetrabutyl 
ammonium bromide (TBAB) was purchased from WWR (West Chester, PA). A (7.55 × 
10-3 M) albendazole solution in acetonitrile containing (0.05M) TBAB as the supporting 
electrolyte was used for this study. All analytical reagents were used as received. DI 
water was used for all other applications. All chemicals were of analytical grade or HPLC 
grade. 
Electrochemical apparatus.  Cyclic voltammetry (CV) and amperometric 
studies were carried out with a computer controlled electrochemical workstation (CHI 
660c, USA) with an ohmic drop (IR) 98% compensated. A three-electrode 
electrochemical cell with a glassy carbon working electrode, a platinum wire as a counter 
electrode, and a Ag/AgCl as the reference electrode were used for all electrochemical 
experiments. The Ag/AgCl reference electrode was equipped with a glass tip, separated 
from the sample solution compartment by a salt-bridge containing KCl and terminating in 
a medium porosity glass frit. Cell resistance, IR, as measured by the CH Instruments, was 
98% compensated in all voltammetric experiments. All work was done at the ambient 
temperature of the laboratory (23℃). 
Electrode surface preparation procedure. The glassy carbon working electrode 
(0.07 cm2) and the platinum wire counter electrode were obtained from Bioanalytical 
Systems Inc. (West Lafayette, IN). Glassy carbon electrodes require polishing in alumina 
(0.1 µm particle sizes) and rinsing thoroughly in pure water and finally ultra-sonicated in 
the same media before use. Prior to this study, glassy carbon electrodes were initially 
polished on one μm diamond polishing paste then ultrasonicated in ethanol and distilled 
13 
 
water successively for 1 minute, followed by rinsing in pure water and then dried in air. 
This step was then followed by alumina polishing and thorough rinsing, as indicated 
above. 
 Chromatographic procedure. The HPLC-UV analysis was carried out using an 
Agilent 1100 series HPLC unit. The UV detector was set at 254 nm wavelength. 
Separations were carried on a ZORBAX XDB-CN column (4.6 mm × 150 mm long and 
five μm particle size, Agilent Technologies). A Zorbax CN guard column (4.6 mm 
cartridge, Agilent Technologies) was used to preserve the analytical column. The mobile 
phase consisted of acetonitrile methanol and DI water (59:27:14). The chromatographic 
run was performed at a flow rate of 1 mL/min. 
Mass spectrometry procedure. The mass spectrometer was a Micromass Quattro 
micro unit. It was set to ESI in positive ion mode. The settings of the mass spectrometer 
were as follows: the desolvation gas (N2) and flow were operated at 500 ℃ and 5 L/min, 
respectively. The corona was operated at 2 μA while the cone voltage was set at 25 V. 
The extractor lens was at 5 V while the RF lens was at 0.2 V. The mass spectrometry 
collision gas was an N2 of high purity (>99.9995). 
Results and Discussion 
Voltammetric oxidation of albendazole.  The electrochemical oxidation of ABZ 
was studied on a glassy carbon electrode surface using cyclic voltammetry. The cyclic 
voltammogram of 7.55 × 10-3 M albendazole solution in acetonitrile was recorded at a 
potential window from 0 V to 2.0 V versus Ag/AgCl reference electrode. The 
voltammogram shows two broad anodic peaks (Figure 3).  
14 
 
 
Figure 3. Cyclic voltammogram of (7.55 × 10-3 M) ABZ in acetonitrile containing 0.05M 
TBAB solution. CV was performed using a glassy carbon electrode at 30 mV/s scan rate. 
 
 
The first peak was at about 1.2 V versus Ag/AgCl reference electrode and the second 
peak occurred at about 1.6 V. During the reverse scan, no reduction peak corresponding 
to the anodic response was observed which indicates that the oxidation of albendazole is 
an irreversible process 39, 56. In a reversible process, a cathodic or reduction peak of about 
the same magnitude of the anodic peak is formed during the reverse scan and vice versa. 
The reversibility or irreversibility of an electrochemical reaction provides significant 
information about the rate at which the electron transfer occurs between the working 
electrode and the redox species in solution. Reversible reactions occur quickly without 
significant thermodynamic barriers. If the electron transfer is not fast enough and the 
electrochemically generated species is not stable, the unstable species undergoes a 
chemical reaction rendering the system irreversible 56. Cyclic voltammetry is an effective 
technique for detecting the formation of reaction intermediates as in the case of ABZ. 
15 
 
Oxidation of ABZ at the electrode surface leads to the formation of albendazole sulfoxide 
which undergoes further oxidation and transformed into albendazole sulfone 45. The first 
and second peak waves in figure 3 were later confirmed using LC-MS to be due to the 
formation of albendazole sulfoxide and albendazole sulfone respectively. The measured 
peak current of the first peak wave was found to increase with the scan rate while the 
second peak also increased accordingly but disappeared at scan rates higher than 100 
mV/S. The disappearance of the second peak indicates that ASON did not form at scan 
rates higher than 100 mV/S.  
The scan rate analysis indicates that the oxidation of albendazole is controlled by 
diffusion. Diffusion of analyte towards the electrode occurs when there is a concentration 
difference between the electrode surface and the bulk solution. As species are reduced or 
oxidized at the electrode surface, a concentration gradient is formed. Molecules move 
from areas of greater concentration to areas of lesser concentration 37 at a rate dictated by 
the concentration gradient. A plot of peak current versus the square root of scan rate (v1/2) 
produced a linear relationship (Figure 4a), suggesting a diffusion-controlled electrode 
process according to the accepted theory 57-58. Increasing the scan rates also increases the 
potential at the electrode surface. As a result, the concentration of analyte at the electrode 
surface becomes smaller, and diffusion towards the electrode surface increases 37. The 
peak potential (Ep) of the anodic peaks were also dependent on the scan rate. Ep shifted to 
more positive potentials on increasing the scan rate. A linear relationship between the 
peak potential and log (scan rate) was obtained (Figure 4b). Such linearity confirms the 
irreversible nature of the electro-oxidation of albendazole 59.  
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Figure 4. Albendazole (7.55 × 10-3 M) in acetonitrile showing peak currents and peak 
potentials: (a) Peak currents versus square root of scan rate; (b) Peak potentials with log 
of scan rate for peak wave at 1.2 V versus Ag/AgCl electrode.  
 
 
 
 
 
Figure 5. Applied potential vs. log 





 ii
i
l
at a scan rate of 100 mV/s; (b) Measured 
current (Ln (ip) versus (E-E1/2) at a scan rate of 100 mV/s for (7.55 x 10
-3 M) albendazole 
in acetonitrile containing 0.05M TBAB at a glassy carbon electrode. 
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Kinetic parameters for albendazole’s oxidation were estimated using experimental 
data obtained from figure 5 above together with equations 1, 2, and 3.  
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Where i is the current at any measured potential and il is the limiting current, α is the 
coefficient of electron transfer, n is the number of electrons transferred, E1/2 is the mid-
point potential, E is the applied potential, T is the temperature in Kelvin (298), R is the 
gas law constant (8.314), F (Faraday constant = 96480), kh is the heterogeneous rate 
constant, A is the area of the electrode surface, and C0 the initial analyte concentration. 
A plot of E versus log 





 ii
i
l
 (Figure 5a) gives a straight line which slope and y-
intercept relate to the charge transfer characteristics. The y-intercept corresponds to the 
value of E1/2 which according to Figure 5a was found to be 0.91V versus Ag/AgCl. The 
plot of Ln ip versus (E-E1/2) (Figure 5b) also gave a straight line whose y-intercept and 
slope provide information to calculate the heterogeneous rate constant and electron 
transfer coefficient using equation 5. For an irreversible system, α is assumed to be 0.5 60. 
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Hence the number of electrons transferred in the electro-oxidation of ABZ to ASOX was 
calculated as 1.3 1. The value of Kh was calculated to be about 1.39 × 104 S-1 cm2. The 
average current density at 100 mV/s was about 214 µA/ cm2 which also supports the 
diffusion-controlled mass transport of albendazole towards the electrode surface.  
Figure 6a shows the plot of peak current versus scan rates for the second peak 
wave obtained during the electro-oxidation of ABZ. This peak was only observed at scan 
rate lower than 100 mV/s and potentials higher than 1.5 V versus Ag/AgCl electrode. A 
linear relationship between peak current and the square root of scan rates was obtained 
for the second peaks as well (Figure 6b). Like the conversion of ABZ to ASOX, this 
indicates that the electron transfer reaction for the conversion of ASOX to AZON is 
diffusion controlled. 
 
 
 
Figure 6. Variation of peak current for (7.55 x 10-3 M) albendazole for second peak 
wave: a) with scan rate b) with square root of scan rate at glassy carbon electrode. 
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A plot of Ep versus scan rate was obtained under the same scan rate values (Figure 
7a). The relationship between the peak potential and log ν was linear (Figure 7b) with a 
correlation coefficient of 0.990. Such behavior reveals the irreversible nature of the 
electrochemical oxidation of ASOX to ASON.  
 
 
 
Figure 7. Variation of peak potential for (7.55 x 10-3 M) albendazole for second peak 
wave: a) with scan rate b) at glassy carbon electrode. 
 
 
Bulk electrolysis analysis. The electrolysis of albendazole (7.5 x 10-3 M) in a 
59:27:14 mixture of acetonitrile, methanol, and deionized water solution was carried out 
using a glassy carbon electrode. The purpose of bulk electrolysis is to completely oxidize 
or reduce the analyte in solution. During bulk electrolysis, the solution is constantly 
stirred to maintain a continuous flow of fresh solution in the vicinity of the electrode 
surface. This type of mass transport is called forced convection, and it is the simplest way 
of transferring the electroactive species to the electrode surface 37. The electro-oxidation 
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of albendazole was investigated as a function of time at two different potentials (1.5 V 
and 1.7 V). First, the electrode potential was fixed at 1.5 V versus Ag/AgCl for six hours. 
1 ml of the electrolyzed solution was drawn out every hour using a syringe and filtered 
using a 0.45 nm filter. The same procedure was carried out at 1.7 V. The solutions were 
analyzed using HPLC and mass spectrometry. 
Chromatographic analysis. Figure 8a shows the chromatograms of ABZ before 
and after 1-5 hours of electrolysis.  The peaks at about 1.9 minutes correspond to 
unreacted ABZ molecules with the highest peak corresponding to albendazole solution 
before electrolysis. After one hour of electrolysis, a chromatographic peak appeared at 
about 1.7 minutes and another smaller peak at about 1.5 minutes. These peaks can be 
attributed to the oxidation products of albendazole. The peak at 1.7 minutes increased 
remarkably as the electrolysis continued while the smaller peak was saturated after three 
hours of electrolysis. The peak due to albendazole (peak at 1.9 min.) decreased as the 
electrolysis proceeded indicating its consumption as the products were formed. Figure 8b 
illustrates the reactant and products profile as a function of electrolysis time.  
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Figure 8. Chromatographic analysis of electrolyzed solution of ABZ: a) sampled at 
different times using UV detector at 254 nm and electrolyzed at 1.5 V versus Ag/AgCl 
electrode and b) reactant and products profile measured as a function of time using the 
chromatographic results obtained from the electrolysis of albendazole. 
 
 
 
a) 
b) 
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Increasing the voltage of electrolysis from 1.5 V to 1.7 V resulted in the formation 
of another chromatographic peak at 2.5 minutes and disappearance of the peak at 1.5 
minutes (Figure 9). This new peak can be correlated to the anodic peak at about 1.6 V 
obtained on the CV of albendazole (Figure 3). Both peaks are likely due to the formation 
of albendazole sulfone. 
 
 
 
Figure 9. Chromatographic analysis of ABZ solution electrolyzed at 1.7 V versus 
Ag/AgCl electrode, sampled at different times using UV detector at 254 nm. 
 
 
 
 
Further characterization of the electro-oxidation products of albendazole was 
carried out with an LC-MS Instrument using the same column and mobile phase flow 
rates as above. Figure 10 shows a mass spectrum of the initial ABZ peak obtained at 1.9 
minutes. The initial drug, labeled A in the figure has well-known fragments with m/z of 
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the molecular ion at 266, other fragments with m/z 234, 191, correspond to structures B 
and C. Wu et al. 55 also observed these fragments during MS analysis of albendazole.  
 
 
 
Figure 10. Mass spectrum of albendazole before electrolysis. Chromatographic peak at 
1.9 minutes. 
 
 
 
 
Figure 11 shows the mass spectra for the chromatographic peak at 1.7 minutes. 
This peak is likely due to the formation of albendazole sulfoxide since it experienced 
steady increase with time of electrolysis. The fragment with m/z 282 (D in figure 11) can 
be attributed to the molecular ion of ASOX. Fragments with m/z of 207 and 239 are 
given as E and F. 
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Figure 11. Mass spectrum of albendazole after electrolysis. Chromatographic peak at 1.7 
minutes. 
 
 
 
Figure 12. Mass spectrum of albendazole after 4 hours of electrolysis. Chromatographic 
peak at 2.5 minutes. 
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Figure 12 shows the mass spectra of the chromatographic peak at 2.5 minutes. 
This peak is thought to represent the formation of albendazole sulphone on the electrode 
surface. The molecular ion peak of albendazole sulphone is likely to be m/z 297. Other 
fragments obtained such as m/z of 159, 206, and 108.95 could not be accounted for. 
Conclusion 
The electrochemical oxidation of albendazole on glassy carbon electrode surface 
followed and ECE (multiple electron transfer with intervening chemical reaction) 
mechanism. Two electrons are transferred during the electrode process although not in a 
concerted fashion. The first step involves oxidation of albendazole followed by a 
chemical reaction and formation of albendazole sulfoxide. In the second step, ASOX is 
oxidized with subsequent formation of albendazole sulfone. The electrode reaction was 
therefore irreversible and limited by diffusion-controlled mass transfer. αn was calculated 
to be 0.652 and Kh was approximately 1.39 × 10
4 S-1 cm2. Bulk electrolysis followed by 
HPLC analysis confirmed the generation of two electrolysis products. The products 
eluded at 1.7 and 2.5 minutes (Figures 14) can be attributed to the formation of 
albendazole sulfoxide and albendazole sulfone respectively. Mass spectra of the 
electrolyzed solution of albendazole reveal peaks at m/z 282 and m/z 297 that can be 
representative of the molecular ions of ASOX and ASON. These results further support 
the formation of these products during electrolysis.  
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Chapter 3 
Electrochemical Reduction of Albendazole on Gold Electrode Surface 
Introduction 
The efficacy of albendazole has been well established for the treatment of 
helminths and related diseases 43 in spite of its low aqueous solubility. Albendazole is 
administered orally and in high dosages in order to achieve therapeutic concentrations 61. 
There has been increased interest in the study of albendazole’s aqueous solubility 62-65 to 
improve the formulation process for oral administration as well as for development of 
systemic formulations. Various studies have shown that albendazole has promising 
anticancer properties against various types of cancer tumors, i.e., colorectal, pancreatic, 
ovarian, breast, and prostate cancer 66-67. However ever, because of its poor solubility, 
albendazole cannot be administered intravenously. None or very little of this drug reaches 
the systemic circulation when administered orally due to erratic absorption and extensive 
first-pass metabolism 64. Therefore, continued research on albendazole is essential. 
Voltammetric techniques have been shown very effective for kinetics and metabolic 
studies of pharmaceutical compounds. Chapter 2 of this work focuses on the 
electrochemical oxidative behavior of albendazole. In this chapter, its reductive behavior 
on gold electrode surface is investigated. 
Experimental Methods 
Chemicals. Acetonitrile, methanol, Tetrabutylammonium bromide (TBAB) were 
purchased from WWR (West Chester, PA). Albendazole was purchased from Sigma 
Aldrich. The albendazole solution was prepared in a 1:1 ratio of acetonitrile/methanol as 
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the solvent containing (TBAB). The TBAB was used as the supporting electrolyte. All 
other chemicals were HPLC grade.  
Electrochemical apparatus. Electrochemistry was carried out with a computer 
controlled electrochemical workstation (CHI 660c, USA) with 99%ohmic drop or IR 
compensation. A gold electrode was used as the working electrode, a platinum wire as the 
counter electrode, and a Ag/AgCl reference electrode were used for all electrochemical 
experiments. The Ag/AgCl was equipped with a glass tip, separated from the sample 
solution compartment by a salt-bridge containing KCl and terminating in a medium 
porosity glass frit. All electrochemical measurements were carried out under ambient 
conditions. 
Electrode surface preparation. The gold working electrode (0.01 cm2) and the 
platinum wire counter electrodes were obtained from Bioanalytical Systems Inc. (West 
Lafayette, IN). The gold electrode was polished using alumina (0.1 mm particle size) and 
rinsed thoroughly in pure water and finally ultra-sonicated in methanol for 1minute, 
followed by rinsing in pure water and then dried in air. 
Bulk electrolysis procedure. The bulk electrolysis reduction of albendazole was 
carried out in tetrabutylammonium bromide-acetonitrile solution under stirring conditions 
for 7 hours. The potential of the reaction was fixed at 1.5 V versus Ag/ AgCl. 100 mL 
aliquots of the reaction mixture were withdrawn every hour. The solution reaction 
mixtures were diluted with mobile phase, filtered and analyzed using chromatographic 
techniques.  
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HPLC procedure. The chromatographic analysis was carried out using an 
Agilent 1100 series HPLC unit. The detector was a UV-Visible with the wavelength set 
at 254 nm. Separations were carried out at room temperature on a C-18 column 
ZORBAX 300SB (4.6X150 mm long and with 3.5 mm particle size, Agilent 
Technologies). The mobile phase consisted of acetonitrile, methanol and de-ionized water 
(59:27:14). The chromatographic run was performed under isocratic conditions at the 
flow rate of 1mL/min.  
Mass spectrometry procedure. The mass spectrometry analysis was performed 
using a Micromass Quattro micro API Mass Spectrometer. The MS was set to ESI in 
positive ion mode. The settings of the mass spectrometer were as follows: the de-
solvation gas (N2) and flow were operated at 1988Cand 249 L/hour respectively. The 
corona was operated at 2 mA, while the cone voltage was set at 60 V. The extractor lens 
was at 3Vwhile the RF lens was set at 0.0 V. The mass spectrometry collision gas was an 
N2 of high purity (>99.9995). 
Results and Discussion 
Voltammetric reduction of albendazole. Reduction of albendazole was 
investigated on gold electrode surface using cyclic voltammetry. A 0.05 M TBAB 
solution was used as the supporting electrolyte to avoid electrolytic migration of ABZ 
molecules as the potential is applied. The reduction was carried out at a potential window 
of 1.0 V to -1.6 V versus Ag/AgCl electrode. The recorded cyclic voltammogram shows 
three well-defined reduction peaks (Figure 13). The first peak was at about -1.0 V versus 
Ag/AgCl reference electrode, the second peak occurred at around -0.6 V, and the third 
peak was registered at +0.1 V. During the reverse scan, no oxidation peaks corresponding 
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to the reduction peaks were observed. This suggests that the reduction of albendazole is 
irreversible. As previously mentioned, in a reversible process, the reverse scan forms a 
cathodic or anodic peak of about the same magnitude of the peak formed during the 
forward scan. As the scan rate was increased, the peak current shifted to more negative 
potentials which also indicates the irreversibility of the system.  
 
 
Figure 13. Scan rate dependence of albendazole. (1.8 x 10-3 M) ABZ dissolved in 
acetonitrile containing 0.05 M TBAB at scan rates taken from 30-180 mV/s. 
 
 
The resulting peak current for the three peak waves was found to increase linearly 
as the scan rate was increased. This linear relationship can be observed in Figure 14 
obtained by plotting the peak current versus the scan rate from 30 mVs-1 to 180 mVs-1 for 
the three peaks. However, at higher scan rates (10-1000 mV/s), the peak current is no 
longer linear with increasing scan rate but preserves its linear relationship with the square 
root of the scan rate as it can be observed in figure 15 (peak centered at around -1.0 V).   
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Figure 14. Peak current as a function of scan rate. (1.8 x 10-3 M) ABZ in acetonitrile 
containing 0.05 M TBAB for the three peaks in figure 17. 
 
 
Figure 15. Peak current of ABZ at scan rates of 10-1000 mV/s. (1.8 x 10-3 M) ABZ in 
acetonitrile containing 0.05 M TBAB for the third peak centered around -1.0 V versus 
Ag/AgCl: A) peak current versus scan rate B) peak current versus square root of scan 
rate. 
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A linear relationship between peak current and square root of scan rate (V1/2) 
suggests a diffusion-controlled reduction process on the electrode surface as it is 
generally accepted 68-69. During cyclic voltammetry studies, the current produced due to 
an electrochemical reaction can be visually observed by studying the obtained cyclic 
voltammogram. The peak current represents the current that diffuses to the electrode 
surface during the electrochemical reaction and can be described by equation 4 below.  
 
  2/12/12/1510229.0 VDACnnip
       Equation 4 
Where A is the electrochemically active surface area, D is the diffusion coefficient, C* is 
the bulk concentration of the analyte, n represents the number of electrons transferred 
during the reaction, α is the coefficient of electron transfer, and V1/2  is the square root of 
the scan rate. The average diffusion coefficient for the electro-reduction of ABZ was 
estimated to be 0.143 x 10-8 cm2/s using the slope of the lines of Figure 16 and equation 
4. 
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Figure 16. Peak current as a function of square root of scan rate. (1.8 x 10-3 M) ABZ in 
acetonitrile containing 0.05 M TBAB for the three peaks in figure 13. 
 
The value of n can be calculated from the slope of the line in Figure 17 (Ep vs. 
log v). For an irreversible electrode process, the linear relationship between peak 
potential and logarithm of the scan rate can be expressed by equation 5 59, 70. 
. 
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Figure 17. Peak potentials (EP) of (1.8 x 10
-3 M) ABZ in acetonitrile containing 0.05 M 
TBAB on gold electrode for the second peak wave. A represents the plot of EP versus 
scan rate, and B represents EP versus log scan rate. 
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Where Ep represents the peak potential, E0 is the formal potential, T is the temperature in 
Kelvin (298), R is the gas law constant (8.314), F (Faraday constant = 96480), k⁰ is the 
standard heterogeneous rate constant,  is the transfer coefficient, n is the number of 
electrons transferred, and v represents the scan rate. The slope was -0.117 and n was 
found to be 0.513. For the third peak n was calculated similarly and was found to be 
0.496. 
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Bulk electrolysis analysis. The three reduction waveforms observed on the cyclic 
voltammograms (Figure 13), indicate that three different species were formed at the gold 
electrode surface during the CV analysis of ABZ. To investigate the species formed, bulk 
electrolysis was carried out to completely electrolyzed the solution and obtain 
quantifiable amounts of the products. The electrolysis was carried over a period of seven 
hours using a gold working electrode, and the potential was set at -1.5 V versus Ag/AgCl. 
7.5 x 10-3 M ABZ solution was constantly stirred during electrolysis to maintain a 
continuous flow of fresh solution to the electrode surface. This type of mass transport 
technique is a simple way of transferring the analyte molecules to the electrode surface 
and achieve complete electrolysis. Complete electrolysis of the ABZ molecules is 
important to recover the necessary amount of product for further characterization. The 
reduction products were monitored every hour using HPLC-MS analysis. 
HPLC-MS analysis of reduction products. In order to characterize the 
reduction products of albendazole, 100 μL aliquots of the electrolyzed solution were 
drawn out every hour and diluted to 1mL before filtration using a 0.45 nm filter. Liquid 
chromatography analysis revealed three major peaks with retention times at 3.4, 3.9 and 
4.4 minutes. The peak at 3.9 minutes corresponds to unreacted ABZ. The peaks at 3.4 and 
4.4 minutes corresponds to the reduction products of ABZ. The chromatogram (Figure 
18) shows a clear increase in the product eluding at 3.4 minutes (peak 1) as the time of 
the electrolysis increases. The product eluting at 4.4 minutes (peak 3) appeared after one 
hour of electrolysis, and its concentration seems to be higher than that of the product 
eluding at 3.4 minutes. Peak 3 increased consistently with the time of electrolysis from 
1hour to 4 hours. However, after seven hours of electrolysis peak 3 decreased noticeably, 
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and peak 1 experienced higher increase. This could indicate that the product eluding at 
3.9 minutes is reacting to form more of the product eluding at 3.4 minutes. The 
concentration of ABZ remained higher than any of the products formed at any time 
during the electrolysis indicating that only a small percentage of the drug was being 
reduced during the seven hours process. 
 
 
Figure 18. Chromatographic analysis of albendazole after electrolysis at – 1.5 V for 
seven hours. 
 
 
 
 
The products formed during the bulk electrolysis of albendazole were further 
analyzed using mass spectrometry in an attempt to identify them. The pure ABZ eluted at 
3.9 minutes (peak 2) on the HPLC chromatogram (Figure 18). The mass spectrum of 
peak 2 includes M/Z of 265, 234, and 307 (Figure 19). The mass spectra of the products 
eluted at 3.4 minutes (Figure 20) shows peaks with M/Z of 240 281, and 284. The 
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presence of peaks with higher M/Z than the initial molecule could indicate initial 
oxidation of albendazole to ASOX. However, further analysis is needed in order to 
identify the products formed during the electrochemical reduction of albendazole.  
 
 
Figure 19. Mass spectrometry of albendazole after electrolysis at – 1.5 V for peak 
eluding at 3.9 minutes. 
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Figure 20. Mass spectrometry of albendazole after electrolysis at – 1.5 V for peak 
eluding at 4.35 minutes. 
 
 
Conclusion  
The cyclic voltammogram obtained during the electrochemical reduction of ABZ 
on gold electrode surface, suggests the formation of three reduction products. By 
examining the CV at different scan rates, it can be asserted that the electrode process was 
irreversible and limited by diffusion-controlled mass transport. The reactions on the 
electrode surface followed and ECE mechanism which allowed the formation of the 
products by an electron transfer reaction followed by a chemical step. αn was calculated 
to be 0.513 and 0.496 for the second and third peak respectively. The reduction products 
of ABZ could not be accurately identified using the obtained HPLC-MS results. Further 
work should include isolation of ABZ reduction products for characterization using 
techniques such as IR and NMR.  
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Chapter 4 
Electrochemical Reduction of Artemisinin 
Introduction 
Artemisinin (Art) and its derivatives (i.e., dihydroartemisinin and artemether) 
constitute the front-line treatment for malaria worldwide. Art is isolated from the Chinese 
plant Artemisia Annua. The use of Artemisia Annua in traditional Chinese medicine 
dates to 168 B.C. for the treatment of fever, helminth infections, and malaria 71.  The 
isolation and structure elucidation of artemisinin was published in 1972 by the Chinese 
scientist Youyou Tu who was partially awarded the 2015 Nobel Prize for medicine for 
this discovery 72. Artemisinin is an enantiomerically pure sesquiterpene lactone. Its 
pharmacophore consists of a 1, 2, 4 trioxane ring containing an endoperoxide bridge 
(Figure 21). Art is very effective against Plasmodium falciparum, the malaria-causing 
parasite. Unfortunately, studies have reported that plasmodium falciparum is becoming 
resistant to artemisinin. Currently, an artemisinin-based combination therapy (ACT) is 
being used to slow down the parasite resistance mechanism. Artemisinin is also being 
investigated as a potential anti-cancer agent. Studies have found that it is highly active 
against different cancer cell lines such as leukemia, colon, and breast cancer 73. In this 
study, the electrochemical reduction behavior of artemisinin was investigated using cyclic 
voltammetry and bulk electrolysis. The reduction products were analyzed using HPLC, 
and HPLC-MS.  
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Figure 21. Structure of artemisinin, a sesquiterpene lactone-containing a 1, 2, 4-trioxane 
ring pharmacophore. 
 
 
 
 
Experimental Methods 
Chemicals. Artemisinin was purchased from Tokyo Chemical Industry Co., TLD. 
Tetrabutylammonium bromide (TBAB) was purchased from WWR (West Chester, PA). 
The artemisinin solutions (0.03 M) were prepared using acetonitrile as the solvent and 
0.05 M TBAB being the supporting electrolyte. A 50:20:30 mixture of Acetonitrile, 
methanol, and deionized water were used for the mobile phase. 
Bulk electrolysis/cyclic voltammetry procedures. The electrochemical analysis 
was carried out with a computer controlled electrochemical workstation (CHI 660c, 
USA) with 98% ohmic drop (IR) compensation. A bulk electrolysis electrochemical cell 
was used for all electrochemical experiments. A gold electrode was used as working 
electrode for cyclic voltammetry analysis. Before use, the gold electrode was polished 
using 1 µm diamond polishing paste then ultra-sonicated in ethanol and distilled water 
successively for 1 min followed by rinsing with water. The electrolysis of artemisinin 
was carried out in ammonium bromide-acetonitrile solution under stirring conditions for 
3hours. The potential of the reaction was fixed at 1.5 V versus Ag/ AgCl. 0.5 mL aliquots 
of the reaction mixture were withdrawn every hour then filtered and analyzed using 
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chromatographic and mass spectrometry techniques. The solvents used were compatible 
with the mobile phase. 
HPLC procedure. The HPLC analysis of artemisinin reduction products was 
carried out on a ZORBAX C-18 300SB column (4.6 x150 mm long and with 3.5 µm 
particle size, Agilent Technologies). The mobile phase consisted of acetonitrile, methanol 
and de-ionized water (50:25:25) respectively with 0.1% formic acid. The HPLC-UV 
analysis was carried out using Agilent 1100 series HPLC unit equipped with an UV-
Visible detector with the wavelength set at 254 nm. The chromatographic run was 
performed under isocratic conditions at the flow rate of 100 µL /min.  
Mass spectrometry procedure. The mass spectrometer (LC/MS Ion Trap 1100 
series) was set to ESI in positive ion mode. Additional settings of the mass spectrometer 
were as follows: Scan mode (standard), range (50-2200) m/z, speed (13,000 m/z/min), 
threshold (1000), nebulizer gas (15.0 psi), and dry gas (5.0 L/min), dry temp (325 °C). 
The target mass was set to 282 while the compound stability and trap drive level were set 
to 100%. The ramp range was from 4500.0 to 1500.0 V. The ms/ms fragmentation amp 
was set to 1.00 V.  
Results and Discussion 
Bulk electrolysis/cyclic voltammetry analysis. Bulk electrolysis and cyclic 
voltammetry analysis of artemisinin were performed using the same setup and conditions 
except the working electrodes were different. The objective of bulk electrolysis was to 
reduce a 0.03M solution of artemisinin in quantitative amounts with the purpose to 
characterize and identify the reduction products. Aliquots of the reaction mixture were 
withdrawn every hour then filtered and analyzed using chromatographic and mass 
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spectrometry techniques. Cyclic voltammograms for the artemisinin solution were 
recorded at 30 minutes intervals during electrolysis. The cyclic voltammograms at 0, 30, 
and 60 minutes are shown in Figure 22.  
 
 
Figure 22. Cyclic voltammograms of Art and electrolyzed Art solutions. The CVs were 
taken after 30 min and 60 min of electrolysis using a gold working electrode at 1.5 V 
potential.  
 
 
The voltammograms taken at 30, and 60 minutes show electrochemical reduction 
of Art as compared to the voltammogram of Art before electrolysis. The broadening of 
existing peaks and formation of new peaks is evidence of reduction product formation. 
Mugweru et al. 74 performed a detailed study of the electron transfer characteristics of 
artemisinin on three different types electrode, a gold (Au), glassy carbon (GC), and 
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pyrolytic graphite (PG) working electrodes. The gold electrode was determined to have 
greater sensitivity towards the reduction of Art. Therefore, the kinetic parameters for the 
electrochemical reaction were obtained using a gold working electrode. According to 
Mugweru et al. 74, the reduction of Art on gold electrode surface is diffusion controlled 
and follows an EC mechanism. The kinetic parameters obtained on this study are reported 
here (Table 2). 
 
Table 2 
 
Electrochemical parameters for reduction of artemisinin on gold (Au), glassy carbon 
(GC), and pyrolytic graphite (PG) working electrodes. 
 
Type of 
working 
electrode 
 
Average  
current density 
(μAcm−2) 
at 100mVs–1 
Diffusion 
coefﬁcient 
(D) (cms−1) 
Electron 
transfer 
coefﬁcient 
(αn) 
Number of  
electrons 
transferred 
(n) 
Rate 
constant 
(kh) 
 
Gold (Au) 
 
    4.62 
 
 
3.34 × 10−6  
 
0.496 
 
1.52  2 
 
23 cm 
s−1 
GC, PG    1.28, 1.53 -- -- -- -- 
 
 
HPLC-MS analysis. The chromatograms in Figure 23 suggest reduction of Art 
and product formation as a function of electrolysis time. The retention time of the drug 
before reduction was determined to be at 25.8 minutes (Figure 23a). After one hour to 
three hours of electrolysis, the development of new peaks due to the formation of 
reduction products is clear as figures 23b and 23c show. To identify the products formed 
by the electrolysis of artemisinin, the solutions were analyzed by mass spectrometry. 
Figure 24a shows the mass spectrum of Art before reduction. The molecular ion can be 
identified with a mass of 282.8, m+1 (283.8), m+2 (284.8) and m + sodium (m+23) 
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(304.8). The mass spectra of electrolyzed Art solutions show masses of possible 
reduction products. Reduction of Art at the C=O bond produces dihydroartemisinin and 
the loss of oxygen from the peroxide bridge produces deoxy artemisinin (Figure 24b). 
According to the mass spectra, it can be deduced that these two products were formed 
although further analysis is needed to confirm this result.  
 
44 
 
 
Figure 23. Chromatograms of artemisinin: a) before electrolysis; b) before and after 1 hr. 
of electrolysis; c) after 2 and 3 hours of electrolysis. 
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Figure 24. Mass spectrometry of artemisinin: a) before electrolysis showing m/z 
corresponding to artemisinin and; b) after 3 hrs. of electrolysis showing m/z for possible 
reduction products deoxy artemisinin and dihydroartemisinin.  
 
 
 
 
b) 
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Conclusion 
Electrochemical reduction of artemisinin was performed during this work. Bulk 
electrolysis of Art, for a three hours period at a fixed reductive potential (1.5 V versus 
Ag/ AgCl), yielded reduction products as the HPLC analysis showed. The cyclic 
voltammograms taken at 30 minutes intervals during electrolysis corroborate these 
findings. Dihydroartemisinin and deoxy artemisinin are thought to be among the products 
formed. Reduction of Art on gold electrode surface follows and EC mechanism. The 
electron process is irreversible and limited by diffusion controlled mass transport as 
reported by 74.  
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Chapter 5 
Hemoglobin Catalyzed Bioactivation of Artemisinin 
Introduction 
The action of artemisinin against malaria parasites is thought to be heme-
mediated, although as of now the detailed mechanism has not been reported 75. 
Understanding the precise mode of action of artemisinin will allow the design of more 
potent analogs for malaria and cancer treatments, and aid in deciphering the resistance 
mechanism from the malaria parasite. plasmodium falciparum goes through several 
stages of development within the host’s red blood cells. Throughout its development, the 
parasite ingests and degrades most of the hemoglobin in host’s cells. Due to this process, 
the parasite digestive vacuole is rich in iron provided by the heme prosthetic group of 
hemoglobin 76. Artemisinin is highly selective towards plasmodium falciparum-infected 
red blood cells. This observation can be used to rationalize the iron-dependent bio-
activation of the endoperoxide group of artemisinin 75. Currently, there are two proposed 
pathways for artemisinin bio-activation the reductive cleavage model and the open 
peroxide model. The reductive cleavage model proposes that artemisinin bio-activation is 
triggered by the reduction of the endoperoxide bond by Fe (II) to generate oxygen 
radicals. The highly reactive oxygen radicals rearrange to generate carbon-centered 
radicals. Primary and secondary carbon-centered radicals have been detected after iron 
activation using electro-paramagnetic resonance spin-trapping techniques. Proponents of 
the open peroxide model argue that carbon radicals cannot exist long enough to have any 
intramolecular interactions. Instead, they propose that artemisinin acts as a source of 
hydrogen peroxide which undergoes a Fenton like reaction to produced hydroxyl radicals 
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capable of irreversibly damaging proteins and other macromolecules. In this model, iron 
behaves like a Lewis acid and facilitates the cleavage of the endoperoxide bond. The non-
peroxidic oxygen is believed to provide stabilization to lower the amount of energy 
required to break the oxygen bridge 75. 
The principal molecular target of artemisinin is yet to be identified. The fact that 
artemisinin can produce different reactive intermediates including carbon and hydroxyl 
radicals indicates that it can interact with a wide range of macromolecules. Various 
research groups have reported the identification of heme-artemisinin adducts by mass 
spectrometry 76. These findings suggest that inhibition of globin formation and 
accumulation of heme within the malaria parasite and cancer cells can cause parasite 
death and cancer cells apoptosis. Other proposed molecular targets of plasmodium 
falciparum are proteins, cell membranes, and mitochondria. Oxidative stress has been 
reported as a cause of cancer cell apoptosis. The mechanism of action of artemisinin 
within cancer cells is believed to be similar the mechanism that causes death to malaria 
parasites. On the other hand, some studies have identified DNA damage caused by 
artemisinin that is independent of oxidative stress. In this research, the reductive mode of 
artemisinin bio-activation was investigated using a carbon nanofibers/hemoglobin-based 
electrochemical biosensor. 
Experimental Methods 
Chemicals. Artemisinin was purchased from Tokyo Chemical Industry CO. LTD. 
Acetonitrile, methanol was purchased from VWR. PSS, Carbon nanofibers and 
hemoglobin (Hb, MW 66,000) were purchased from Sigma Chemical Co. The nanofibers 
had a diameter 100 nm diameter and a variable length between 20-200 μm. They were 
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used without further purification. A concentrated (0.004 M) ART solution was made in 
20 mM acetate buffer pH 5.5 containing 1% methanol. The solution was used as a stock 
solution for all other experiments. Hemoglobin was used without any additional 
purification. All other chemicals were HPLC grade. 
Electrochemical procedures. Cyclic voltammetry and amperometric analysis 
were carried out with a computer controlled electrochemical workstation (CHI 660c, 
USA) with 98% ohmic drop (IR) compensation. A three-electrode electrochemical cell 
was used for all electrochemical experiments. A glassy carbon electrode (0.07 cm2) and a 
pyrolytic carbon electrode were used as working electrode while a platinum wire as 
counter electrode. The Ag/AgCl reference electrode was equipped with a glass tip 
separated from the sample solution compartment by a salt-bridge containing saturated 
KCl and terminating in a medium porosity glass frit. Before use, glassy carbon electrodes 
were polished using 1 µm diamond polishing paste then ultra-sonicated in ethanol and 
distilled water successively for 1 min followed by rinsing with water. All electrochemical 
measurements were carried out under ambient conditions.  
Hemoglobin/PSS biosensor preparation. A pyrolytic Carbon working electrode 
was used to prepare the biosensor. A thin slice of the electrode was cut off to expose a 
pristine electrode surface before the assembly. 2µL of a 45mg/ml of hemoglobin solution 
in acetate buffer (pH 5.5) was set on the pyrolytic carbon electrode surface and then left 
to dry at room temperature. A second layer consisting of 2µL of PSS solution in DI water 
was set on the hemoglobin modified electrode and allowed to dry at room temperature. 
The electrode was rinsed with DI water to removes any unattached material. The 
electrochemical cell contained 10 ml of 20 mM acetate buffer pH 5.5 as the supporting 
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electrolyte solution. To avoid oxygen interference, the electrolyte solution was purged 
with nitrogen gas (N2) for five minutes to remove the oxygen before the analysis.  
Hemoglobin/CNFs biosensor preparation. The biosensor was assembled using 
a glassy carbon (GC) electrode. The GC electrode surface was modified using carbon 
nanofibers (CNFs). 2 µL of a 2mg/ml suspension of CNFs in DMS was carefully placed 
on the surface of a previously cleaned GC electrode and allowed to dry at room 
temperature. A second layer consisting of 2µL of a 45mg/ml of hemoglobin solution in 
acetate buffer (pH 5.5) was set on the CNFs modified electrode and allowed to dry at 
room temperature. The electrochemical cell contained 10 ml of 20 mM acetate buffer pH 
5.5 as the supporting electrolyte solution. To avoid oxygen interference, the electrolyte 
solution was purged with nitrogen gas (N2) for five minutes to remove the oxygen prior 
to the analysis. 
Results and Discussion  
Hemoglobin/polystyrene sulphonate (PSS) biosensor. Hemoglobin is an 
oxygen-transporting protein found in red blood cells. It includes four heme prosthetic 
groups each containing an iron molecule in the center. Due to the presence of Iron (II), 
the heme groups are electroactive which makes hemoglobin an ideal recognition 
molecule for assembling electrochemical biosensors. Immobilization of hemoglobin on 
the electrode surface is a critical step since the immobilization procedure may alter its 
normal behavior. Hemoglobin’s conformation must be kept intact for it to remain active 
after immobilization. There are many different methods for immobilizing enzymes onto 
the electrode. One of the simplest methods is to entrap the enzyme between the electrode 
and a dialysis membrane or a polymeric film. This biosensor was prepared by entrapping 
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a hemoglobin solution between the surface of a pyrolytic carbon electrode and a film of 
polystyrene sulfonate. Several layers of hemoglobin and PSS were assembled to improve 
the results. The voltammogram taken before purging with nitrogen showed a well define 
reduction peak due to the presence of oxygen in solution. After purging the solution with 
nitrogen gas, the cyclic voltammetric results did not show well-defined reduction and 
oxidation peaks. Well-defined redox peaks are expected after purging. Otherwise, the 
biosensor may not be assembled correctly. These results could indicate that good contact 
between hemoglobin and the sensing material was not achieved or that the enzyme was 
denatured during the assembly. A different method using carbon nanofibers to 
immobilize hemoglobin was utilized to continue the experiment. 
Carbon nanofibers (CNFs)/ hemoglobin biosensor. Carbon nanomaterials such 
as carbon nanotubes, graphite powder, and carbon nanofibers are ideal materials for 
construction of biosensors due to their excellent conductivity, large surface area, and 
biocompatibility. According to Vamvakaki et al. 77, carbon nanofibers are superior to 
carbon nanotubes or graphite powder for direct immobilization of enzymes onto their 
surface since CNFs have larger functionalized surface area. Also, CNFs’ high porosity 
and absorption ability support enzyme immobilization 78. Therefore, CNFs were preferred 
to assemble this biosensor. A layer consisting of 2 µL of a 2mg/ml suspension of CNFs in 
DMS was placed on the polished glassy carbon electrode’s surface and allowed to dry.  
Subsequently, a layer of the hemoglobin solution was placed on the CNFs modified 
electrode and allowed to dry before analyzing it. Figure 2 shows a schematic of the 
biosensor assembly.  
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Figure 25. Schematic representation for assembly of GC/CNFs/Hb biosensor. 
 
 
The biosensor was tested prior to the study of artemisinin by evaluating 
hemoglobin bioactivity using cyclic voltammetry. After purging the solution with 
nitrogen to drive out the oxygen, reduction and oxidation peaks are observed due to the 
redox reaction of iron in hemoglobin. During the forward scan iron (II) is oxidized to iron 
(III) while during the reverse scan iron (III) is reduced and becomes iron (II) again. 
Consistent results after purging the solution confirm the reliability of the biosensor and 
the favorable conformation and bioactivity of hemoglobin. Artemisinin was added to the 
electrochemical cell containing 10 ml of acetate buffer. 0.2 ml of artemisinin solution 
was added incrementally to obtain greater concentration after each addition. The solution 
was analyzed after each Art addition using cyclic voltammetry. Figure 26 shows the 
cyclic voltammogram of some selected concentrations of artemisinin. As clearly 
illustrated in the figure, the voltammogram at 0.0 µM of artemisinin is completely 
reversible. This is due to the iron in hemoglobin been oxidized and subsequently reduced 
at the electrode surface. After addition of 0.8 µM of artemisinin, the oxidation peak is 
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noticeably decreased, and the reduction peak increases. This trend continues as the 
concentration of artemisinin is increased. At 5.8 µM, the oxidation peak is mostly gone.  
 
 
 
Figure 26. Cyclic voltammograms obtained from reduction of Art using Hb/CNFs 
biosensor, at (0.0 µM, 0.8 µM, 1.2 µM, 2.6 µM, 5.8 µM) of artemisinin.  
 
 
 
In this case, artemisinin is being reduced by iron (II) which is consequently 
oxidized to iron (III). The results indicate that hemoglobin catalyzes artemisinin’s 
peroxide bridge reduction and subsequent radical formation is possible. Studies have 
shown that after reduction of artemisinin, oxygen and carbon-centered radicals are 
formed 79. These very reactive radical species are thought to be responsible for the 
eradication of the malaria parasite and cancer cells.  
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Hemoglobin-catalyzed reduction of artemisinin. Reduction of artemisinin on 
glassy carbon electrode surface was investigated by Mugweru et al. 74. The peak potential 
was found to be - 0.85 V versus Ag/AgCl reference electrode. In this work, peak potential 
of hemoglobin anchored onto carbon nanofibers is about -0.30 V vs. Ag/AgCl. The 
reduction potential of artemisinin on CNFs/Hb modified glassy carbon electrode averages 
at about – 0.375 V vs. Ag/AgCl. The results show the electrocatalytic effect of 
hemoglobin towards the reduction of artemisinin. The reduction potential of artemisinin 
was catalytically reduced by about 475 mV. Hemoglobin anchored on CNFs must be 
properly oriented such that the heme prosthetic group can interact with artemisinin during 
the electrochemical analysis. The catalytic activity of hemoglobin toward artemisinin 
correlates closely with the orientation of the heme groups in Hb 78. A line Weaver-Burke 
plot (Figure 27) was obtained using the peak current produced with increasing 
concentration of artemisinin. The Michaelis–Menten constant (Km) for Art reduction on 
CNF/Hb modified glassy carbon electrode was determined using the Weaver-Burke plot 
and equations 6 and 7. 
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Figure 27. Line Weaver-Burk plot using GC/CNFs/Hb voltammograms. 
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Where Km represents the Michaelis-Menten constant, which indicates the enzyme-
substrate kinetics. Iss is the steady-state current obtained from GC /CNF/Hb CV 
measurements. Imax is the maximum current obtained from CVs at saturated Art solutions. 
The apparent Km for this system was found to be 0.093 mM according to the kinetic 
studies. Table 3 compares the Km for hemoglobin from several literature articles and this 
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study based on the surface the enzyme is immobilized as well as the substrate under 
study. The Km value for hemoglobin in solution is about three times smaller than that 
found in this study which makes sense given that the enzyme was not immobilized. 
Therefore, it was free to interact with the substrate. 
 
Table 3 
Michaelis-Menten constant (Km) of hemoglobin immobilized on different materials’ 
surfaces.  
Materials Substrates Km (mM) References 
Iron nanoparticles Hydrogen peroxide 0.29                  80 
mesoporous silica Hydrogen peroxide 2.87                  81 
in solution Artemisinin 0.028                   82 
Carbon nanofibers Artemisinin 0.093             This study 
 
 
Effect of artemisinin concentration. Figure 26 shows cyclic voltammograms of 
GC/CNF/Hb modified electrode obtained at increasing concentration of Art. The peak 
current increases as the concentration of Art is increased. The catalytic peak current 
increases linearly with Art concentrations between 0 and 200 μM (Figure 28). This linear 
relationship was used to estimate the sensitivity of GC/CNF/Hb modified electrode for 
Art catalysis. The linear relationship showed the slope as 0.329 mA/mM with a 
regression coefficient of (R = 0.99436).  
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Figure 28. Current versus concentration of artemisinin obtained from cyclic 
voltammograms. 
 
 
Effect of scan rate. The cyclic voltammogram of CNFs/Hb modified glassy 
carbon electrode at 100 mV/s exhibits well-defined redox peaks at −0.22 V and −0.38 V 
vs. Ag/AgCl (Figure 29).  The formal potential (E0’) was −0.30 V vs. Ag/AgCl. CVs 
were also taken at scan rates of 100 mV/s and 200 mV/s in the presence of 0.20 mM ART 
solution (Figure 30). At 200 mV/s, the CV exhibits both the oxidation and reduction 
peaks as in CVs taken in the absence of artemisinin while at 100 mV/s, the oxidation 
peak is gone. This indicates that at scan rates 100 mV/s and lower Art reacts with 
HbFe(II) rendering the system irreversible. The magnitude of the scan rate affects the 
system in that at higher scan rates, electron transfer between iron and the electrode is fast 
enough so that the chemical step does not occur. Therefore, a reversible behavior is 
observed.  
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Figure 29. Cyclic voltammogram of CNFs/Hb modified GC electrode. CV taken in 20 
mM acetate buffer pH 5.5 at 100 mV/s-1. 
 
 
 
Figure 30. Cyclic voltammograms of GC/CNFs/Hb taken at 100 and 200 mV/s-1 scan 
rates. The CVs were carried out in 20 mM acetate buffer pH 5.5 containing 0.2 mM Art.  
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Amperometric analysis of CNFs/Hb biosensor. The CNFs/hemoglobin 
biosensor was analyzed further using Amperometry to confirm its reliability and 
corroborate the results obtained by cyclic voltammetry. For this experiment, the 
electrochemical cell was set up similar to that for cyclic voltammetry. Addition of 
constant amounts of artemisinin to the electrochemical cell, containing 10 ml of the 
electrolyte solution, was done at 200 seconds intervals to allow the resulting current to 
equilibrate. The resulting current due to the reduction of artemisinin increased as the 
concentration of artemisinin in solution was increased. These results suggest that the 
biosensor worked as expected and that reductive bioactivation of artemisinin by HbFe(II) 
occurred on the electrode surface. 
Conclusion  
A sensitive carbon nanofiber/hemoglobin biosensor was assembled which was 
able to detect catalytic bioactivation of artemisinin by heme-bound iron (Fe II) using 
cyclic voltammetry. The GC/CNF/Hb system was also able to detect increased Art 
concentration in solution. The catalytic current generated upon subsequent additions of 
0.2 ml Art solution was proportional to the concentration of Art in the electrochemical 
cell. This result shows that the assembled GC/CNF/Hb biosensor can be used for the 
determination of unknown concentration of analytes. From the cyclic voltammograms 
obtained, it can be inferred that hemoglobin was strongly anchored onto the CNFs’ 
surface. Well defined cathodic and anodic peaks were observed for the GC/CNF/Hb 
system in the absence of artemisinin. In the presence of artemisinin, a well-defined 
cathodic peak is observed. This implies that the conformation of hemoglobin in this 
system was very favorable. The Michaelis-Menten constant (Km) of hemoglobin towards 
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Art reduction was 0.093 mM. From literature, other similar systems with hemoglobin 
immobilized on different materials generated higher Km values.  
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